Literature DB >> 20862683

Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score.

Brian M Feldman1, Sharon M Funk, Britt-Marie Bergstrom, Nichan Zourikian, Pamela Hilliard, Janjaap van der Net, Raoul Engelbert, Pia Petrini, H Marijke van den Berg, Marilyn J Manco-Johnson, Georges E Rivard, Audrey Abad, Victor S Blanchette.   

Abstract

OBJECTIVE: Repeated hemarthrosis in hemophilia causes arthropathy with pain and dysfunction. The Hemophilia Joint Health Score (HJHS) was developed to be more sensitive for detecting arthropathy than the World Federation of Hemophilia (WFH) physical examination scale, especially for children and those using factor prophylaxis. The HJHS has been shown to be highly reliable. We compared its validity and sensitivity to the WFH scale.
METHODS: We studied 226 boys with mild, moderate, and severe hemophilia at 5 centers. The HJHS was scored by trained physiotherapists. Study physicians at each site blindly determined individual and total joint scores using a series of visual analog scales.
RESULTS: The mean age was 10.8 years. Sixty-eight percent were severe (93% of whom were treated with prophylaxis), 15% were moderate (24% treated with prophylaxis), and 17% were mild (3% treated with prophylaxis). The HJHS correlated moderately with the physician total joint score (rs=0.42, P<0.0001) and with overall arthropathy impact (rs=0.42, P<0.0001). The HJHS was 97% more efficient than the WFH at differentiating severe from mild and moderate hemophilia. The HJHS was 74% more efficient than the WFH at differentiating subjects treated with prophylaxis from those treated on demand. We identified items on the HJHS that may be redundant or rarely endorsed and could be removed from future versions.
CONCLUSION: Both the HJHS and WFH showed evidence of strong construct validity. The HJHS is somewhat more sensitive for mild arthropathy; its use should be considered for studies of children receiving prophylaxis.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2011        PMID: 20862683     DOI: 10.1002/acr.20353

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  35 in total

1.  Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.

Authors:  Beth Boulden Warren; Dianne Thornhill; Jill Stein; Michael Fadell; J David Ingram; Sharon Funk; Kristi L Norton; Heidi D Lane; Carolyn M Bennett; Amy Dunn; Michael Recht; Amy Shapiro; Marilyn J Manco-Johnson
Journal:  Blood Adv       Date:  2020-06-09

2.  Issues in the measurement of quality of life in hemophilia.

Authors:  Brian M Feldman
Journal:  Rev Bras Hematol Hemoter       Date:  2013

3.  Gait Alteration Due to Haemophilic Arthropathies in Patients with Moderate Haemophilia.

Authors:  Alban Fouasson-Chailloux; Fabien Leboeuf; Yves Maugars; Marc Trossaert; Pierre Menu; François Rannou; Claire Vinatier; Jérome Guicheux; Raphael Gross; Marc Dauty
Journal:  Int J Environ Res Public Health       Date:  2022-06-20       Impact factor: 4.614

4.  Quantitative versus semiquantitative MR imaging of cartilage in blood-induced arthritic ankles: preliminary findings.

Authors:  Andrea S Doria; Ningning Zhang; Bjorn Lundin; Pamela Hilliard; Carina Man; Ruth Weiss; Gary Detzler; Victor Blanchette; Rahim Moineddin; Felix Eckstein; Marshall S Sussman
Journal:  Pediatr Radiol       Date:  2014-02-13

5.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

6.  Quality of life and its predictors among adult patients with haemophilic arthropathy. An observational study.

Authors:  Roberto Ucero-Lozano; José Antonio López-Pina; Alba Ortiz-Pérez; Rubén Cuesta-Barriuso
Journal:  BMC Musculoskelet Disord       Date:  2021-05-15       Impact factor: 2.362

7.  Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada.

Authors:  J St-Louis; D J Urajnik; F Ménard; S Cloutier; R J Klaassen; B Ritchie; G E Rivard; M Warner; V Blanchette; N L Young
Journal:  BMC Hematol       Date:  2016-05-05

8.  Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.

Authors:  Terry Mizrahi; Jean St-Louis; Nancy L Young; Francine Ménard; Nichan Zourikian; Evemie Dubé; Georges E Rivard
Journal:  BMC Hematol       Date:  2016-11-08

9.  Manual therapy in the treatment of patients with hemophilia B and inhibitor.

Authors:  Rubén Cuesta-Barriuso; Roberto O Trelles-Martínez
Journal:  BMC Musculoskelet Disord       Date:  2018-01-22       Impact factor: 2.362

10.  Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.

Authors:  Katharine Batt; Michael Recht; David L Cooper; Neeraj N Iyer; Christine L Kempton
Journal:  Patient Prefer Adherence       Date:  2017-08-09       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.